問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Cardiovascular Diseases

Division of Cardiovascular Diseases

Kaohsiung Municipal Ta-Tung Hospital (在職)

更新時間：2023-09-19

盧怡旭Lu, Ye-Hsu
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

42Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

盧怡旭

List

85Cases

2009-01-01 - 2013-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)

  • Condition/Disease

    Acute Coronary Symdrome

  • Test Drug

    SCH530348

Participate Sites
13Sites

Terminated13Sites

2014-01-01 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2019-05-02 - 2026-01-17

Phase III

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  • Condition/Disease

    Coronary Heart Disease (CHD)

  • Test Drug

    Repatha

Participate Sites
10Sites

Recruiting9Sites

Terminated1Sites

2023-04-13 - 2027-05-05

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2023-03-01 - 2027-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Recruiting17Sites

2023-01-30 - 2024-12-29

Phase II

A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

  • Condition/Disease

    Type 2 Diabetes Mellitus、Obesity、Overweight

  • Test Drug

    AMG133

Participate Sites
4Sites

Recruiting4Sites

2014-01-31 - 2018-04-30

Phase IV

高血管風險之第2型糖尿病病患使用LINAgliptin 5 mg每天1次的一項多中心、國際性、隨機分配、平行分組、雙盲、安慰劑對照、心血管安全性及腎臟微血管結果試驗。

  • Condition/Disease

    DM

  • Test Drug

    Trajenta® (BI 1356)

Participate Sites
4Sites

Terminated4Sites

2014-12-01 - 2017-07-21

Phase III

A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial

  • Condition/Disease

    Cardiovascular Disease

  • Test Drug

    AMG 145

Participate Sites
8Sites

Terminated8Sites

2009-02-15 - 2012-09-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Terminated16Sites

2021-05-18 - 2023-12-31

Phase II

A Phase 2b, Randomised, Double-Blind, Active-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure and Chronic Kidney Disease

  • Condition/Disease

    Heart Failure

  • Test Drug

    AZD9977及Dapagliflozin

Participate Sites
10Sites

Not yet recruiting5Sites

Recruiting5Sites

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB